Judith Sys1, Simon Van Cleynenbreugel1, Mieke Deschodt2,3, Lorenz Van der Linden4,5, Jos Tournoy6,7. 1. Department of Geriatric Medicine, University Hospitals Leuven, Herestraat 49, Leuven, 3000, Belgium. 2. Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Herestraat 49, Leuven, 3000, Belgium. 3. Nursing Science, Department of Public Health, University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland. 4. Pharmacy Department, University Hospitals Leuven, Herestraat 49, Leuven, 3000, Belgium. 5. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, Leuven, 3000, Belgium. 6. Department of Geriatric Medicine, University Hospitals Leuven, Herestraat 49, Leuven, 3000, Belgium. jos.tournoy@uzleuven.be. 7. Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Herestraat 49, Leuven, 3000, Belgium. jos.tournoy@uzleuven.be.
Abstract
PURPOSE: Insomnia is highly prevalent in older persons and significantly impacts quality of life, functional abilities, and health status. It is frequently treated with benzodiazepines or Z-drugs. Due to adverse events, an increased use of alternative sedative medications has been observed in older adults. We aimed to study the efficacy and safety of alternative sedative medications for treating insomnia in older people, excluding benzodiazepines and Z-drugs. METHODS: We conducted a systematic search of MEDLINE (PubMed), EMBASE, and the Cochrane Central register of Controlled Trials databases. We included randomized controlled trials and prospective and retrospective quasi-experimental studies, conducted in patients older than 65 years, without psychiatric or neurological comorbidities. RESULTS: The systematic search yielded 9483 articles, of which 24 were included in this review, describing nine different sleep medications in total. No clear beneficial impact on sleep could be demonstrated in studies investigating the impact of melatonin (n = 10), paroxetine (n = 1), diphenhydramine (n = 1), tiagabine (n = 2), and valerian (n = 1). Ramelteon slightly improved sleep latency (n = 4), while doxepin was found to provide a sustained sleep improvement with a safety profile that was comparable to placebo (n = 3). Suvorexant showed an improved sleep maintenance with only mild side effects (n = 1). One study detected increased adverse effects of trazodone after 3 months but did not evaluate the effect on sleep. CONCLUSIONS: The overall level of evidence was limited, making it difficult to draw robust conclusions. Preliminary evidence points towards suvorexant, doxepin, and possibly ramelteon as effective and safe pharmacological alternatives for treating insomnia in older adults.
PURPOSE:Insomnia is highly prevalent in older persons and significantly impacts quality of life, functional abilities, and health status. It is frequently treated with benzodiazepines or Z-drugs. Due to adverse events, an increased use of alternative sedative medications has been observed in older adults. We aimed to study the efficacy and safety of alternative sedative medications for treating insomnia in older people, excluding benzodiazepines and Z-drugs. METHODS: We conducted a systematic search of MEDLINE (PubMed), EMBASE, and the Cochrane Central register of Controlled Trials databases. We included randomized controlled trials and prospective and retrospective quasi-experimental studies, conducted in patients older than 65 years, without psychiatric or neurological comorbidities. RESULTS: The systematic search yielded 9483 articles, of which 24 were included in this review, describing nine different sleep medications in total. No clear beneficial impact on sleep could be demonstrated in studies investigating the impact of melatonin (n = 10), paroxetine (n = 1), diphenhydramine (n = 1), tiagabine (n = 2), and valerian (n = 1). Ramelteon slightly improved sleep latency (n = 4), while doxepin was found to provide a sustained sleep improvement with a safety profile that was comparable to placebo (n = 3). Suvorexant showed an improved sleep maintenance with only mild side effects (n = 1). One study detected increased adverse effects of trazodone after 3 months but did not evaluate the effect on sleep. CONCLUSIONS: The overall level of evidence was limited, making it difficult to draw robust conclusions. Preliminary evidence points towards suvorexant, doxepin, and possibly ramelteon as effective and safe pharmacological alternatives for treating insomnia in older adults.
Entities:
Keywords:
Aged; Antidepressant; Hypnotics and sedatives; Insomnia; Older adults; Sleep
Authors: Andrew D Krystal; H Heith Durrence; Martin Scharf; Philip Jochelson; Roberta Rogowski; Elizabeth Ludington; Thomas Roth Journal: Sleep Date: 2010-11 Impact factor: 5.849
Authors: Jonathan J Baskett; Joanna B Broad; Philip C Wood; John R Duncan; Megan J Pledger; Judie English; Josephine Arendt Journal: Age Ageing Date: 2003-03 Impact factor: 10.668
Authors: Jennifer L Schroeck; James Ford; Erin L Conway; Kari E Kurtzhalts; Megan E Gee; Krista A Vollmer; Kari A Mergenhagen Journal: Clin Ther Date: 2016-10-15 Impact factor: 3.393
Authors: Martin Scharf; Roberta Rogowski; Steven Hull; Martin Cohn; David Mayleben; Neil Feldman; Larry Ereshefsky; Alan Lankford; Thomas Roth Journal: J Clin Psychiatry Date: 2008-10-07 Impact factor: 4.384
Authors: Qilong Xin; Robin K Yuan; Kirsi-Marja Zitting; Wei Wang; Shaun M Purcell; Nina Vujovic; Joseph M Ronda; Stuart F Quan; Jonathan S Williams; Orfeu M Buxton; Jeanne F Duffy; Charles A Czeisler Journal: Sleep Date: 2022-07-11 Impact factor: 6.313
Authors: Martin Schulze Westhoff; Adrian Groh; Sebastian Schröder; Phileas Johannes Proskynitopoulos; Kirsten Jahn; Martin Klietz; Benjamin Krichevsky; Dirk O Stichtenoth; Felix Wedegärtner; Stefan Bleich; Helge Frieling; Johannes Heck Journal: J Neural Transm (Vienna) Date: 2022-09-02 Impact factor: 3.850